{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:06:26Z","timestamp":1793048786869,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Advanced systemic mastocytosis (AdvSM), a clonal hematologic neoplasm driven predominantly by D816V-mutant KIT, is often characterized by organ damage. Associated hematologic neoplasms (AHNs; usually myeloid) are often present, leading to poor survival. We report on the oral, highly selective, potent KIT D816V inhibitor avapritinib (200 mg once daily, starting dose) with &amp;gt;4 years follow-up from the fully enrolled PATHFINDER study. End points included overall response rate (ORR; primary), duration of response (DOR), progression-free survival (PFS), overall survival (OS), changes in objective biomarkers of disease, and safety (all secondary). Of 107 patients with AdvSM (including 71 [66%] with SM-AHN; overall population median follow-up, 49 months), 83 were response-evaluable. ORR was 73% (95% confidence interval, 63-83). Median DOR was 58 months; PFS, 51 months, and OS, 62 months. Disease progression occurred in 21 of 107 patients (20%), predominantly in SM-AHN and largely driven by the AHN. Reductions in objective biomarkers of disease were observed. Most frequent (\u226530% patients) treatment-emergent adverse events (TEAEs; any grade; grade \u22653) were thrombocytopenia (58%; 31%); periorbital edema (57%; 6%), anemia (54%; 33%), peripheral edema (48%; 2%), and diarrhea (36%; 5%). Adverse events of special interest were cognitive effects (34%; 8%) and intracranial bleeds (4%; 2%). Eleven (10%) patients experienced TEAEs leading to death, of which 1 was deemed related to avapritinib by the principal investigator. With 4-year follow-up, patients with AdvSM treated with avapritinib experienced deep and durable responses and a favorable benefit-risk profile. This trial was registered at www.ClinicalTrials.gov as #NCT03580655.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017519","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:01:11Z","timestamp":1769634071000},"page":"3676-3689","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-6156","authenticated-orcid":false,"given":"Jason","family":"Gotlib","sequence":"first","affiliation":[{"name":"1Division of Hematology, Stanford Cancer Institute\/Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Reiter","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti H.","family":"Radia","sequence":"additional","affiliation":[{"name":"3Guy\u2019s and St Thomas\u2019s NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-4473","authenticated-orcid":false,"given":"Iv\u00e1n","family":"\u00c1lvarez-Twose","sequence":"additional","affiliation":[{"name":"4Institute of Mastocytosis Studies of Castilla-La Mancha, Virgen del Valle Hospital, Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2987-1331","authenticated-orcid":false,"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-7847","authenticated-orcid":false,"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[{"name":"6ARUP Laboratories, Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6316-3112","authenticated-orcid":false,"given":"Jens","family":"Panse","sequence":"additional","affiliation":[{"name":"7Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany"},{"name":"8Center for Integrated Oncology, Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Mital","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Transplantology, Medical University of Gda\u0144sk, Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Pettit","sequence":"additional","affiliation":[{"name":"5Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"10Center for Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"12Department of Hematology, French National Reference Center for Mastocytosis, Necker-Enfants Malades Hospital, Assistance publique\u2013H\u00f4pitaux de Paris, and Imagine Institute, INSERM U1163, Paris University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Elshoury","sequence":"additional","affiliation":[{"name":"13Innovative Hematology and Indiana Hemophilia and Thrombosis Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5275-6868","authenticated-orcid":false,"given":"Cristina Bulai","family":"Livideanu","sequence":"additional","affiliation":[{"name":"14Department of Dermatology, Centre of Reference for Mastocytosis, Toulouse University Hospital, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Mesa","sequence":"additional","affiliation":[{"name":"15Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-6213","authenticated-orcid":false,"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[{"name":"16Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy, Section of Bone Marrow Transplantation and Cellular Therapy, Rush Medical College, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7318-2093","authenticated-orcid":false,"given":"Massimo","family":"Triggiani","sequence":"additional","affiliation":[{"name":"17Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-3069","authenticated-orcid":false,"given":"Ingunn","family":"Dybedal","sequence":"additional","affiliation":[{"name":"18Departments of Hematology and Pharmacology, Oslo University Hospital, Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Jurcic","sequence":"additional","affiliation":[{"name":"19Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Zanotti","sequence":"additional","affiliation":[{"name":"20Hematology Unit, Department of Medicine, University Hospital of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-5400","authenticated-orcid":false,"given":"Stephen T.","family":"Oh","sequence":"additional","affiliation":[{"name":"21Siteman Cancer Center at Barnes-Jewish Hospital and Washington University, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5293-4620","authenticated-orcid":false,"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[{"name":"22Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth O.","family":"Hexner","sequence":"additional","affiliation":[{"name":"23Abramson Cancer Center, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"24Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie G.","family":"Lee","sequence":"additional","affiliation":[{"name":"25Department of Medicine, St. Michael\u2019s Hospital, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R.","family":"Sperr","sequence":"additional","affiliation":[{"name":"26Department of Medicine, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0288-8248","authenticated-orcid":false,"given":"Elizabeth A.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"27Leukemia Division, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8072-2614","authenticated-orcid":false,"given":"Matthew","family":"Butler","sequence":"additional","affiliation":[{"name":"28Department of Medicine, Mays Cancer Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0767-1504","authenticated-orcid":false,"given":"Johannes","family":"L\u00fcbke","sequence":"additional","affiliation":[{"name":"2Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilda","family":"Bidollari","sequence":"additional","affiliation":[{"name":"29Blueprint Medicines Corporation, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Lin","sequence":"additional","affiliation":[{"name":"29Blueprint Medicines Corporation, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Rylova","sequence":"additional","affiliation":[{"name":"30Blueprint Medicines (Switzerland) GmbH, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u0161a","family":"Dimitrijevi\u0107","sequence":"additional","affiliation":[{"name":"30Blueprint Medicines (Switzerland) GmbH, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier I.","family":"Mu\u00f1oz-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"30Blueprint Medicines (Switzerland) GmbH, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"31Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"7","key":"2026052610373987800_bib1","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ajh.26962","article-title":"Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management","volume":"98","author":"Pardanani","year":"2023","journal-title":"Am J Hematol"},{"issue":"5","key":"2026052610373987800_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23672","article-title":"Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis","volume":"89","author":"Kristensen","year":"2014","journal-title":"Am J Hematol"},{"issue":"7","key":"2026052610373987800_bib3","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"issue":"16","key":"2026052610373987800_bib4","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.3390\/cancers14163942","article-title":"Clinical outcomes of adults with systemic mastocytosis: a 15-year multidisciplinary experience","volume":"14","author":"Ungerstedt","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026052610373987800_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, prognosis, and risk factors in mastocytosis","volume":"34","author":"Brockow","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"2026052610373987800_bib6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"issue":"5","key":"2026052610373987800_bib7","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jaci.2012.10.015","article-title":"Prevalence of indolent systemic mastocytosis in a Dutch region","volume":"131","author":"van Doormaal","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2026052610373987800_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/1651-226X.2024.31406","article-title":"Epidemiology of mastocytosis: a population-based study (Sweden)","volume":"63","author":"Bergstrom","year":"2024","journal-title":"Acta Oncol"},{"key":"2026052610373987800_bib9","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.12688\/f1000research.19463.1","article-title":"Recent advances in the understanding and therapeutic management of mastocytosis","volume":"8","author":"Rossignol","year":"2019","journal-title":"F1000Res"},{"issue":"20","key":"2026052610373987800_bib10","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/cncr.34420","article-title":"Patient-reported outcomes among patients with systemic mastocytosis in routine clinical practice: results of the TouchStone SM Patient Survey","volume":"128","author":"Mesa","year":"2022","journal-title":"Cancer"},{"issue":"1","key":"2026052610373987800_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"2026052610373987800_bib12","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International Prognostic Scoring System for mastocytosis (IPSM): a retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol"},{"issue":"26","key":"2026052610373987800_bib13","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"2026052610373987800_bib14","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2026052610373987800_bib15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"2026052610373987800_bib16","volume-title":"Systemic mastocytosis","author":"Verstovek","year":"2024"},{"issue":"6","key":"2026052610373987800_bib17","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.3390\/ijms22062983","article-title":"Response criteria in advanced systemic mastocytosis: evolution in the era of KIT inhibitors","volume":"22","author":"Shomali","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2026052610373987800_bib18","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1016\/j.jaip.2020.05.005","article-title":"Importance of adequate diagnostic workup for correct diagnosis of advanced systemic mastocytosis","volume":"8","author":"Schwaab","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"21","key":"2026052610373987800_bib19","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/bloodadvances.2018020628","article-title":"Impact of somatic and germline mutations on the outcome of systemic mastocytosis","volume":"2","author":"Mu\u00f1oz-Gonz\u00e1lez","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2026052610373987800_bib20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"2026052610373987800_bib21","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3390\/cells9112512","article-title":"The genomics of myelodysplastic syndromes: origins of disease evolution, biological pathways, and prognostic implications","volume":"9","author":"Awada","year":"2020","journal-title":"Cells"},{"issue":"10","key":"2026052610373987800_bib22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"issue":"31","key":"2026052610373987800_bib23","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.19.00640","article-title":"MARS: Mutation-Adjusted Risk Score for advanced systemic mastocytosis","volume":"37","author":"Jawhar","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026052610373987800_bib24","unstructured":"Blueprint Medicines Corporation. AYVAKIT (avapritinib)\n          . Prescribing information. 2024. Accessed 7 October 2025. https:\/\/www.blueprintmedicines.com\/wp-content\/uploads\/uspi\/AYVAKIT.pdf."},{"key":"2026052610373987800_bib25","unstructured":"Blueprint Medicines Corporation. AYVAKYT (avapritinib)\n          . Summary of product characteristics. 2024. EMA. Accessed 7 October 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ayvakyt#product-information-section."},{"issue":"12","key":"2026052610373987800_bib26","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"2026052610373987800_bib27","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat Med"},{"issue":"21","key":"2026052610373987800_bib28","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1182\/bloodadvances.2022007539","article-title":"Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis","volume":"6","author":"Reiter","year":"2022","journal-title":"Blood Adv"},{"key":"2026052610373987800_bib29","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Horny","year":"2017"},{"issue":"8","key":"2026052610373987800_bib30","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41375-022-01615-z","article-title":"Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis","volume":"36","author":"Reiter","year":"2022","journal-title":"Leukemia"},{"key":"2026052610373987800_bib31","doi-asserted-by":"crossref","first-page":"107919","DOI":"10.1016\/j.leukres.2025.107919","article-title":"Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: a retrospective real-world external control study","volume":"157","author":"Reiter","year":"2025","journal-title":"Leuk Res"},{"issue":"16","key":"2026052610373987800_bib32","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1200\/JCO.21.01849","article-title":"Superior efficacy of midostaurin over cladribine in advanced systemic mastocytosis: a registry-based analysis","volume":"40","author":"L\u00fcbke","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026052610373987800_bib33","article-title":"Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM registry","author":"Kennedy","year":"2022","journal-title":"Blood Adv"},{"key":"2026052610373987800_bib34","author":"Gotlib","year":"6  2020"},{"issue":"16","key":"2026052610373987800_bib35","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.2019000932","article-title":"New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis","volume":"135","author":"Reiter","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2026052610373987800_bib36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41408-024-01157-w","article-title":"Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy","volume":"14","author":"Huang","year":"2024","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026052610373987800_bib37","first-page":"103398","article-title":"Advanced Systemic Mastocytosis with associated haematological neoplasm: treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant","volume":"71","author":"Sriskandarajah","year":"2023","journal-title":"Curr Res Transl Med"},{"key":"2026052610373987800_bib38","author":"Christen","year":"14-17  2024"},{"issue":"4","key":"2026052610373987800_bib39","first-page":"699","article-title":"Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee","volume":"38","author":"McLornan","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"2026052610373987800_bib41","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.7326\/M22-1460","article-title":"Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update","volume":"175","author":"DeTora","year":"2022","journal-title":"Ann Intern Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3676\/2519766\/blooda_adv-2025-017519-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3676\/2519766\/blooda_adv-2025-017519-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:37:46Z","timestamp":1779806266000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3676\/566305\/Efficacy-and-safety-of-avapritinib-in-advanced"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017519","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,15]]}}}